Teva- Pharmaceutical Industries Return on Equity

Teva- Pharmaceutical Industries (TEVA) currently reports a ROE of 19.01%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Teva- Pharmaceutical Industries's ROE history and peer comparisons.

Teva- Pharmaceutical Industries's ROE of 19.01% is lower than the Healthcare sector average of 29.39%. That is roughly 35.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Teva- Pharmaceutical Industries's current 19.01% should be judged against Healthcare norms (sector average: 29.39%) and against TEVA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 19.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Teva- Pharmaceutical Industries, and consider following TEVA for alerts when major investors trade the stock.

Teva- Pharmaceutical Industries is classified in the Healthcare sector. On ROE, it currently shows 19.01% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TEVA with unrelated industries.